ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
This year saw more readjustments from the pandemic
The journalist and producer will begin his new role in February
Structural biologists track neurodegeneration-linked proteins
2023 was marked by several first-time approvals, while some previously approved drugs came under scrutiny
Long before naloxone was an OTC drug, this retired paramedic used it in the field
Nearly a decade after Agilent stopped making the instruments, researchers work to keep old systems running
Ableist attitudes in STEM responsible for pay disparities, researcher says
Las barreras lingüísticas que frenan a los investigadores rara vez se contemplan en las conversaciones sobre diversidad en ciencia
The moments, numbers, and news that the C&EN team found noteworthy this year
In both Cambridge, Massachusetts, and Cambridge, England, the firm will hunt for new drug targets in the genetic diversity of individual cells
Nearly a decade after Agilent stopped making the instruments, researchers work to keep old systems running
Microscopy method follows copolymer growth in real time at the level of individual monomers